United Arab Emirates · Bentham Science Publishers B...

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription

Recent Patents on Inflammation and Allergy Drug Discovery

Recent Patents on Inflammation and Allergy Drug Discovery is a journal indexed in SJR in Medicine (miscellaneous) and Drug Discovery with an H index of 29. It has a best quartile of Q1.

ISSN: 1872-213X

Publisher: Bentham Science Publishers B.V.

Category: Medicine (miscellaneous)

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

NPD Q1

H-index 29

Acceptance rate pie_chart

36%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

SJR Impact

—

H-index

Docs (year)

Docs 3y

Total refs

Cites 3y

282

Citable 3y

Cites/Doc 2y

5.9

Ref/Doc

0.0

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Editorial

Work Related Asthma in the Textile Industry

Heme Oxygenase-1 and Carbon Monoxide: Emerging Therapeutic Targets in Inflammation and Allergy

Has Bevacizumab (Avastin) Given Extra Therapeutic Gain in Metastatic Colorectal Cancer and Malignant Brain Gliomas? Systematic Review Answering this Question

Glaucoma Eye Drops Adverse Skin Reactions

Formulation of Nanoparticles Against TB - A Review

Food Allergy: From the of Loss of Tolerance Induced by Exclusion Diets to Specific Oral Tolerance Induction

Ferulic Acid: A Promising Therapeutic Phytochemical and Recent Patents Advances

Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models

Exocrine Pancreas Involvement in Celiac Disease: A Review

Evaluation of the Effect of a-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property

Effect of Tetracyclines on IgE Allergic Responses and Asthma

SHOW MORE ARTICLES

Editorial: [Monoclonal Antibodies in the Treatment of Asthma(Guest Editor: Moshe Ben-Shoshan)]

Advancement in Shampoo (A Dermal Care Product): Preparation Methods, Patents and Commercial Utility

Determinants of Grip Strength in Tunisian Nurses: A Bicentric Study

Daclizumab: A Potential Asthma Therapy?

Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis

Chitinases: Therapeutic Scaffolds for Allergy and Inflammation

Antipsoriatic Drug Development: Challenges and New Emerging Therapies

Antileukotriene Treatment in Children with Asthma - New Patents

Anti-Inflammatory Approaches that Target the Chemokine Network

Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles

Antagonism of Eosinophil Accumulation in Asthma

Anaphylaxis: An Update on its Understanding and Management

FAQs

SJR is not available (NPD) for Recent Patents on Inflammation and Allergy Drug Discovery in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Recent Patents on Inflammation and Allergy Drug Discovery is 36%.

Recent Patents on Inflammation and Allergy Drug Discovery

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Recent Patents on Inflammation and Allergy Drug Discovery?

What is the APC / publication cost?

What is the acceptance rate?